| DESCRIPTION | - "A report of a Task Group of Committee 2 of the International Commission on Radiological Protection", Basic anatomical and physiological data for use in radiological protection: The Skeleton in Annals of the ICRP, (1995), vol. 25, pages 58 - 68 | - |
| DESCRIPTION | - BAEKSGAARD ET AL., CANCER CHEMOTHER PHARACOL, (2003), vol. 51, pages 187 - 92 | - |
| DESCRIPTION | - BERG, TRANSPLANT PROC., (1998), vol. 30, no. 8, pages 3975 - 3977 | - |
| DESCRIPTION | - BETTS ET AL., J IMMUNOL METHODS, (2003), vol. 281, page 6578 | - |
| DESCRIPTION | - BIERER ET AL., CURR. OPIN. IMMUN, (1993), vol. 5, pages 763 - 773 | - |
| DESCRIPTION | - BIGLER ET AL., HEALTH PHYS, (1976), vol. 31, pages 213 - 218 | - |
| DESCRIPTION | - BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426 | - |
| DESCRIPTION | - BONDANZA ET AL., BLOOD, (2006), vol. 107, pages 1828 - 1836 | - |
| DESCRIPTION | - BONYHADI, J IMMUNOL, (2005), vol. 174, pages 2366 - 2375 | - |
| DESCRIPTION | - BRENTJENS, CLIN CANCER RES, (2007), vol. 13, pages 5426 - 5435 | - |
| DESCRIPTION | - BRENTJENS ET AL., MOLECULAR THERAPY, (2010), vol. 18, no. 4, pages 666 - 668 | - |
| DESCRIPTION | - BRENTJENS ET AL., MOL THER, (2010), vol. 18, pages 666 - 8 | - |
| DESCRIPTION | - CARPENITO ET AL., PROC NATL ACAD SCI U S A, (2009), vol. 106, pages 3360 - 3365 | - |
| DESCRIPTION | - CARPENITO ET AL., PROC NATL ACAD SCI U S A, (2009), vol. 1, no. 06, pages 3360 - 3365 | - |
| DESCRIPTION | - DOHNER ET AL., BLOOD, (1995), vol. 85, pages 1580 - 1589 | - |
| DESCRIPTION | - DOHNER ET AL., BLOOD, (1995), vol. 85, pages 1580 - 9 | - |
| DESCRIPTION | - DROPULIC ET AL., HUMAN GENE THERAPY, (2006), vol. 17, pages 577 - 88 | - |
| DESCRIPTION | - DULL ET AL., J VIROL, (1998), vol. 72, pages 8463 - 71 | - |
| DESCRIPTION | - GARLAND, J. IMMUNOL MCTH., (1999), vol. 227, no. I-2, pages 53 - 63 | - |
| DESCRIPTION | - GHOSH ET AL., GLYCOBIOLOGY, (1991), vol. 5, pages 505 - 10 | - |
| DESCRIPTION | - GRIBBEN, BIO! BLOOD MARROW TRANSPLANT, (2011), vol. 17, pages S63 - S70 | - |
| DESCRIPTION | - GRIBBEN ET AL., BIOL BLOOD MARROW TRANSPLANT, (2011), vol. 17, pages S63 - S70 | - |
| DESCRIPTION | - HAANEN ET AL., J. EXP. MED., (1999), vol. 190, no. 9, page 131 91328 | - |
| DESCRIPTION | - HALLEK ET AL., BLOOD, (2008), vol. 111, page 5446 | - |
| DESCRIPTION | - HARRIS ET AL., EUR J RADIOL, (2010), vol. 75, pages E97 - EL0T | - |
| DESCRIPTION | - HARTSOCK, AM J CLIN PATH, (1965), vol. 43, pages 326 - 331 | - |
| DESCRIPTION | - HENDERSON ET AL., IMMUN, (1991), vol. 73, pages 316 - 321 | - |
| DESCRIPTION | - HENDERSON ET AL., IMMUN., (1991), vol. 73, pages 316 - 321 | - |
| DESCRIPTION | - HOUSTON, PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883 | - |
| DESCRIPTION | - HURWITZ ET AL., INT J CANCER, (1979), vol. 23, pages 174 - 180 | - |
| DESCRIPTION | - JANETZKI, IMMUNITY, (2009), vol. 31, pages 527 - 528 | - |
| DESCRIPTION | - JENA ET AL., BLOOD, (2010), vol. 1 16, pages 1035 - 1044 | - |
| DESCRIPTION | - JENA ET AL., BLOOD, (2010), vol. 116, pages 1035 - 44 | - |
| DESCRIPTION | - JOHNSON ET AL., BLOOD, (2009), vol. 114, pages 535 - 46 | - |
| DESCRIPTION | - JUNE ET AL., NAT REV IMMUNOL, (2009), vol. 9, pages 704 - 16 | - |
| DESCRIPTION | - KERSHAW, CLIN CANCER RES, (2006), vol. 12, pages 6106 - 15 | - |
| DESCRIPTION | - KERSHAW ET AL., CIIN CANCER RES, (2006), vol. 12, pages 6106 - 6115 | - |
| DESCRIPTION | - KERSHAW ET AL., CLIN CANCER RES, (2006), vol. 12, pages 6106 - 15 | - |
| DESCRIPTION | - KERSHAW ET AL., CLIN CANCER RES, (2006), vol. 12, pages 6106 - 6115 | - |
| DESCRIPTION | - LAMANNA ET AL., J CLIN ONCOL, (2006), vol. 24, pages 1575 - 81 | - |
| DESCRIPTION | - LAMERS ET AL., J CLIN ONCO1, (2006), vol. 24, pages E20 - E22 | - |
| DESCRIPTION | - LAMERS, J CLIN ONCOL, (2006), vol. 24, pages E20 - E22 | - |
| DESCRIPTION | - LAPORT ET AL., BLOOD, (2003), vol. 102, pages 2004 - 2013 | - |
| DESCRIPTION | - LEE ET AL., CANCER RES, (2011), vol. 71, pages 2871 - 2881 | - |
| DESCRIPTION | - LEVINE ET AL., PROC NATL ACAD SCI U S A, (2006), vol. 103, pages 17372 - 17377 | - |
| DESCRIPTION | - LIU, CELL, (1991), vol. 66, pages 807 - 815 | - |
| DESCRIPTION | - MACALLAN ET AL., EUR J IMMUNOL, (2003), vol. 33, pages 2316 - 26 | - |
| DESCRIPTION | - MILONE ET AL., MOL THER, (2009), vol. 17, pages 1453 - 1464 | - |
| DESCRIPTION | - MILONE ET AL., MOL THER., (2009), vol. 17, pages 1453 - 1464 | - |
| DESCRIPTION | - MILONE ET AL., MOL THER, (2009), vol. 17, pages 1453 - 64 | - |
| DESCRIPTION | - MILONE, MOL THER, (2009), vol. 17, pages 1453 - 1464 | - |
| DESCRIPTION | - MOLINA, ANN REV MED, (2008), vol. 59, pages 237 - 50 | - |
| DESCRIPTION | - MORGAN ET AL., MOLECULAR THERAPY, (20100223), pages 1 - 9 | - |
| DESCRIPTION | - MORGAN ET AL., MOL THER, (2010), vol. 18, pages 843 - 51 | - |
| DESCRIPTION | - NALDINI ET AL., SCIENCE, (1996), vol. 272, pages 263 - 7 | - |
| DESCRIPTION | - PARK ET AL., MOL THER, (2007), vol. 15, page 825833 | - |
| DESCRIPTION | - PORTER ET AL., BLOOD, (2006), vol. 107, pages 1325 - 31 | - |
| DESCRIPTION | - PULE ET AL., NAT MED, (2008), vol. 14, pages 1264 - 1270 | - |
| DESCRIPTION | - PULE ET AL., NAT MED, (2008), vol. 14, pages 1264 - 70 | - |
| DESCRIPTION | - PULE, NAT MED, (2008), vol. 14, pages 1264 - 1270 | - |
| DESCRIPTION | - RAPOPORT ET AL., NAT, (2005), vol. 1, no. 1, pages 1230 - 1237 | - |
| DESCRIPTION | - ROEDERER, NAT MED, (1995), vol. 1, pages 621 - 7 | - |
| DESCRIPTION | - ROSENBERG, NEW ENG. J. OF MED., (1988), vol. 319, page 1676 | - |
| DESCRIPTION | - SABBAGH ET AL., TRENDS IMMUNOL, (2007), vol. 28, pages 333 - 339 | - |
| DESCRIPTION | - SADELAIN ET AL., CURR OPIN IMMUNOL, (2009), vol. 21, pages 215 - 23 | - |
| DESCRIPTION | - SORROR, BLOOD, (2008), vol. 111, pages 446 - 52 | - |
| DESCRIPTION | - TILL ET AL., BLOOD, (2008), vol. 1 12, pages 2261 - 2271 | - |
| DESCRIPTION | - TILL ET AL., BLOOD, (2008), vol. 112, pages 2261 - 2271 | - |
| DESCRIPTION | - TILL ET AL., BLOOD, (2008), vol. 112, pages 2261 - 71 | - |
| DESCRIPTION | - UCKUN ET AL., BLOOD, (1988), vol. 71, pages 13 - 29 | - |
| DESCRIPTION | - UI-TEI ET AL., FEBS LETTERS, (2000), vol. 479, pages 79 - 82 | - |
| DESCRIPTION | - WOODARD ET AL., PHYS MED BIOL, (1960), vol. 5, pages 57 - 59 | - |
| DESCRIPTION | - ZUFFEREY ET AL., NATURE BIOTECHNOL, (1997), vol. 15, pages 871 - 875 | - |
| OPPOSITION | - Alignment of SEQ ID NO : 24 with the sequences of isoforms 1 and 2 of the human CD 3 zeta domain, URL: https://blast.ncbi.nlm.nih.gov/Blast.cgi | - |
| OPPOSITION | - "FMC63-28Z receptor protein [synthetic construct]", Protein, (20120611), Database accession no. ADM64594.1, URL: NCBI, XP055622886 | - |
| OPPOSITION | - "Guideline on quality, non-clinical and clinical aspects of medical products containing genetically modified cells", EMA/CAT/GTWP/671639/2008 Rev.1, (20190726), pages 1 - 29, XP055621273 | - |
| OPPOSITION | - "Guideline on the evaluation of anticancer medicinal products in man", EMA/CHMP/205/95 Rev.5, (20170922), pages 1 - 43, XP055621264 | - |
| OPPOSITION | - "Homo sapiens CD247 molecule (CD247), transcript variant 2, mRNA", Nucleotide, (20161006), Database accession no. NM_000734.4, URL: NCBI, XP055533900 | - |
| OPPOSITION | - KOCHENDERFER, J.N. et al., "Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor", J. Immunother., (20090900), vol. 32, no. 7, doi:10.1097/CJI.0b013e3181ac6138, ISSN 1524-9557, pages 689 - 702, XP009133189 | - |
| OPPOSITION | - Molecular Therapy Information, URL: https://www. cell .com/pb-assets/journals/society/molecular- therapy/Authors_ MT.pdf | - |
| OPPOSITION | - "Study NCT01029366", Clinicaltrials.gov Archive website for the clinical trial NCT01029366, (20091209), pages 1 - 7, URL: https://clinicaltrials.gov/ct2/show/NCTO_1029366?term=NCT0 1 029366&rank= 1, XP055621236 | - |
| OPPOSITION | - Supplementary material available online at NEJM.org | - |
| OPPOSITION | - "T-cell surface glycoprotein CD3 zeta chain isoform 2 precursor [Homo sapiens]", Genbank, (20190716), Database accession no. NP_000725.1, XP003030111 | - |
| OPPOSITION | - "T-cell surface glycoprotein CD3 zeta chain", UniProt/ Swiss Prot, (19910201), Database accession no. P20963, XP055622938 | - |
| OPPOSITION | - NICHOLSON et al., "Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma", Mo/. Immunol., (19970000), vol. 34, no. 16-17, doi:10.1016/S0161-5890(97)00144-2, pages 1157 - 1165, XP055532770 | |
| OPPOSITION | - NICHOLSON et al., "Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma", Molecular Immunology, (19970000), vol. 34, no. 16-17, pages 1157 - 1165, XP055532770 | |
| OPPOSITION | - NICHOLSON et al., "Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma", Mol. Immunol., (19970000), vol. 34, no. 16-17, doi:10.1016/S0161-5890(97)00144-2, ISSN 0161-5890, pages 1157 - 1165, XP055532770 | |
| OPPOSITION | - NICHOLSON, I.C. et al., "Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma", Molecular Immunology, (19970000), vol. 34, no. 16-17, doi:10.1016/S0161-5890(97)00144-2, ISSN 0161-5890, pages 1157 - 1165, XP055532770 | |
| OPPOSITION | - SHEN, Z. et al., "Engineering Peptide Linkers for scFv Immunosensors", Analytical Chemistry, (20080000), vol. 80, no. 6, doi:10.1021/ac7018624, ISSN 0003-2700, pages 1910 - 1917, XP055036568 | |
| OPPOSITION | - MILONE et al., "Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo", Journal of the American Society of Gene Therapy, (20090421), vol. 17, no. 8, doi:10.1038/mt.2009.83, ISSN 1525-0016, page 1453, XP002732433 | |
| OPPOSITION | - MILONE et al., "Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo", Journal of the American Society of Gene Therapy, (20090421), vol. 17, no. 8, doi:10.1038/mt.2009.83, pages 1453 - 1464, XP002732433 | |
| OPPOSITION | - MILONE et al., "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo", MOLECULAR THERAPY, (20090800), vol. 17, no. 8, ISSN 1525-0016, pages 1453 - 1464, XP002732433 | |
| OPPOSITION | - MILONE, M.C. et al., "Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo", Molecular Therapy, (20090400), vol. 17, no. 8, doi:10.1038/mt.2009.83, ISSN 1525-0016, pages 1453 - 1464, XP002732433 | |
| OPPOSITION | - KOHN et al., "CARs on Track in the Clinic", Molecular Therapy, (20110300), vol. 19, no. 3, doi:10.1038/mt.2011.1, ISSN 1525-0016, pages 432 - 438, XP055122212 | |
| OPPOSITION | - HOLOHAN et al., "Cancer drug resistance: an evolving paradigm", Nature Reviews, (20130000), vol. 13, no. 10, pages 714 - 726, XP055252550 | |
| OPPOSITION | - IMAI, C. et al., "Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia", Leukemia, (20040000), vol. 18, no. 4, doi:10.1038/sj.leu.2403302, ISSN 0887-6924, pages 676 - 684, XP002579934 | |
| OPPOSITION | - IMAI et al., "Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia", Leukemia, (20040000), vol. 18, no. 4, doi:10.1038/sj.leu.2403302, pages 676 - 684, XP002579934 | |
| OPPOSITION | - IMAI et al., "Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia", Leukemia, (20040212), vol. 18, no. 4, doi:10.1038/sj.leu.2403302, ISSN 0887-6924, pages 676 - 684, XP002579934 | |
| OPPOSITION | - IMAI et al., Leukemia, (20040212), vol. 18, no. 4, doi:10.1038/sj.leu.2403302, ISSN 0887-6924, pages 676 - 684, XP002579934 | |
| OPPOSITION | - PORTER, D.L. et al., "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", The New England Journal of Medicine, (20110000), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, pages 725 - 733, XP055579937 | |
| OPPOSITION | - PORTER et al., "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", The NEJM, (20110800), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, pages 725 - 733, XP055579937 | |
| OPPOSITION | - PORTER et al., "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", The New England Journal of Medicine, (20110825), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, page 725, XP055579937 | |
| OPPOSITION | - PORTER et al., "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", The New England Journal of Medicine, (20110825), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, pages 725 - 733, XP055579937 | |
| OPPOSITION | - CARPENITO et al., "Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains", PNAS, (20090300), vol. 106, no. 9, pages 3360 - 3365, XP002605939 | |
| OPPOSITION | - TAMMANA SYAM et al., "4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies", Human Gene Therapy, (20100100), vol. 21, no. 1, doi:10.1089/hum.2009.122, ISSN 1043-0342, pages 75 - 86, XP002732432 | |
| OPPOSITION | - KALOS et al., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Science Translational Medicine, (20110810), vol. 3, no. 95, page 95ra73, XP002667262 | |
| OPPOSITION | - KALOS et al., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Science Translational Medicine, (20111008), vol. 3, no. 95, page 95ra73, XP002667262 | |
| OPPOSITION | - KALOS et al., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Sci Trans1 Med, (20110810), vol. 3, no. 95, page 95ra73, XP002667262 | |
| OPPOSITION | - KALOS, M. et al., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Science Translational Medicine, (20110000), vol. 3, no. 95, doi:10.1126/scitranslmed.3002842, ISSN 1946-6234, page 95ra73, XP002667262 | |
| OPPOSITION | - COOPER, L. J. N. et al., "T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect", Blood, (20030000), vol. 101, no. 4, pages 1637 - 1644, XP055204920 | |
| OPPOSITION | - JENA, B. et al., "Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor", Blood, (20100500), vol. 116, no. 7, doi:10.1182/blood-2010-01-043737, ISSN 0006-4971, pages 1035 - 1044, XP055021403 | |
| OPPOSITION | - JENA et al., "Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor", Blood, (20100503), vol. 116, no. 7, doi:10.1182/blood-2010-01-043737, ISSN 0006-4971, pages 1035 - 1044, XP055021403 | |
| OPPOSITION | - KOCHENDERFER et al., "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19", Blood, (20100728), vol. 116, doi:10.1182/blood-2010-04-281931, pages 4099 - 4102, XP002667047 | |
| OPPOSITION | - KOCHENDERFER et al., "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19", Blood, (20100728), vol. 116, no. 20, doi:10.1182/blood-2010-04-281931, ISSN 0006-4971, pages 4099 - 4102, XP002667047 | |
| OPPOSITION | - KOCHENDERFER et al., "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19", Blood, (20100728), vol. 116, no. 20, pages 4099 - 4102, XP002667047 | |
| OPPOSITION | - DAVILA et al., "Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma", Blood, (20101206), vol. 116, no. 17, doi:10.1182/blood-2010-05-282780, ISSN 0006-4971, page 3268, XP055305384 | |
| OPPOSITION | - Green Monty et al., "Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma", Blood, (20101206), vol. 116, no. 17, doi:10.1182/blood-2010-05-282780, ISSN 0006-4971, pages 3268 - 3277, XP055305384 | |
| OPPOSITION | - ZENZ et al., "Risk categories and refractory CLL in the era of chemoimmunotherapy", Blood, (20120306), vol. 119, no. 18, doi:10.1182/blood-2011-11-, pages 4101 - 4107, XP055621207 | |
| OPPOSITION | - RAMOS, C.A. et al., "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", Expert Opinion on Biological Therapy, (20110000), vol. 11, no. 17, doi:10.1517/14712598.2011.573476, ISSN 1471-2598, pages 855 - 873, XP055122639 | |
| OPPOSITION | - BENMEBAREK et al., "Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells", Int J Mol Sci, (20190000), vol. 20, no. 1283, doi:10.3390/ijms20061283, ISSN 1661-6596, pages 1 - 21, XP055605605 | |
| OPPOSITION | - DAVILA et al., "How do CARs work? : Early insights from recent clinical studies targeting CD19", Oncoimmunology, (20120000), vol. 1, no. 9, doi:10.4161/onci.22524, ISSN 2162-4011, pages 1577 - 1583, XP055445746 | |
| OPPOSITION | - PORTER et al., "Chimeric Antigen Receptor Therapy for B-cell Malignancies", Journal of Cancer, (20110106), vol. 2, doi:10.7150/jca.2.331, ISSN 1837-9664, page 331, XP055247868 | |
| OPPOSITION | - PORTER et al., "Chimeric Antigen Receptor Therapy for B-cell Malignancies", Journal of Cancer, (20110106), vol. 2, doi:10.7150/jca.2.331, ISSN 1837-9664, pages 331 - 332, XP055247868 | |
| OPPOSITION | - PORTER et al., "Chimeric Antigen Receptor Therapy for B-cell Malignancies", Journal of Cancer, (20110601), vol. 2, doi:10.7150/jca.2.331, ISSN 1837-9664, pages 331 - 332, XP055247868 | |
| SEARCH | - MILONE MICHAEL C ET AL, "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY AUG 2009, (200908), vol. 17, no. 8, ISSN 1525-0024, pages 1453 - 1464, XP002732433 [AD] 1-18 * abstract * * page 1454, column l, paragraph 1 - column r, paragraph 1 * * page 1455, column r, paragraph l - page 1461, column l, paragraph 2 * | |
| SEARCH | - DAVID L. PORTER ET AL., "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia", THE NEW ENGLAND JOURNAL OF MEDICINE, (20110825), vol. 365, no. 8, pages 725 - 733, XP002732435 [AP] 1-18 * abstract * * page 726, column r, paragraph 1; figure 1 * * page 730, column l, paragraph 2 - page 733, column l, paragraph 1 * | |
| SEARCH | - CARPENITO CARMINE ET AL, "Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (200903), vol. 106, no. 9, ISSN 0027-8424, pages 3360 - 3365, XP002732434 [A] 1-18 * abstract * * page 3360, column r, paragraph 2 - page 3361, column r, paragraph 2 * * page 3362, column l, paragraph 2 - paragraph 3 * * page 3363, column r, paragraph 2 - page 3364, column r2 * | |
| SEARCH | - TAMMANA SYAM ET AL, "4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies", HUMAN GENE THERAPY, (201001), vol. 21, pages 75 - 86, XP002732432 [A] 1-18 * abstract * * page 75, column r, paragraph 2 - page 76, column l, paragraph 2 * * page 77, column r, paragraph 3 - page 78, column l, paragraph 1; figure 1 * * page 81, column r, paragraph 1 - page 84, column r, paragraph 1 * | |
